Bernat Olle, Vedanta Biosciences CEO
Vedanta brings home a win for lead microbiome program, passing a PhII test and clinching BARDA investment
Vedanta Biosciences wrapped up a Series D about two months ago to advance its microbiome research, but it’s not content to rest on its laurels.
The Cambridge, MA-based biotech claimed a win in a Phase II study treating Clostridioides difficile infection, saying its lead program achieved a statistically significant reduction in recurrences after eight weeks compared with placebo. It’s a result that ostensibly impressed the US government as the study results triggered a $23.8 million option from BARDA.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters